[Federal Register: January 5, 2005 (Volume 70, Number 3)]
[Notices]
[Page 913-914]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr05ja05-86]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2004N-0479]
Draft Risk Assessment of Streptogramin Resistance in Enterococcus
faecium Attributable to the Use of Streptogramins in Animals; Extension
of Comment Period
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; extension of comment period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is extending to
February 23, 2005, the comment period for the notice that appeared in
the Federal Register of November 24, 2004 (69 FR 68384). In the notice,
FDA requested comments on a draft risk assessment of the potential
impact that food-animal use of streptogramin antimicrobials has on the
resistance to chemically similar streptogramins used to treat human
enterococcal infections. The agency is taking this action in response
to a request for an extension to allow interested persons additional
time to submit comments.
DATES: Submit written and electronic comments by February 23, 2005.
ADDRESSES: Submit written comments to the Division of Dockets
Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane,
rm. 1061, Rockville, MD 20852. Submit electronic comments to http://frwebgate.access.gpo.gov/cgi-bin/leaving.cgi?from=leavingFR.html&log=linklog&to=http://www.fda.gov/dockets/ecomments
.
FOR FURTHER INFORMATION CONTACT: Barry Hooberman, Center for Veterinary
Medicine (HFV-102), Food and Drug Administration, 7500 Standish Pl.,
Rockville, MD 20855, 301-827-8557, e-mail: bhooberm@cvm.fda.gov.
SUPPLEMENTARY INFORMATION:
I. Background
In the Federal Register of November 24, 2004 (69 FR 68384), FDA
published a notice with a 60-day comment period to request comments on
a draft risk assessment of the potential impact that food-animal use of
streptogramin antimicrobials has on the resistance to chemically
similar streptogramins used to treat human enterococcal infections. The
veterinary drug of interest in this risk assessment is the
streptogramin, virginiamycin, a drug approved for use in chicken,
turkey, swine, and cattle feed. FDA will consider information received
during the comment period in its preparation of a final risk
assessment.
The agency has received a request for a 60-day extension of the
comment period for the notice. This request conveyed concern that the
current 60-day comment period does not allow sufficient time to develop
a meaningful or thoughtful response to the notice.
[[Page 914]]
FDA has considered the request and is extending the comment period
for the notice for an additional 30 days, until February 23, 2005. The
agency believes that a 30-day extension allows adequate time for
interested persons to submit comments without significantly delaying
the preparation of the final risk assessment.
II. Request for Comments
Interested persons may submit to the Division of Dockets Management
(see ADDRESSES) written or electronic comments on this document. Submit
a single copy of electronic comments or two paper copies of any mailed
comments, except that individuals may submit one paper copy. Comments
are to be identified with the docket number found in brackets in the
heading of this document. Received comments may be seen in the Division
of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday.
Dated: December 28, 2004.
William K. Hubbard,
Associate Commissioner for Policy and Planning.
[FR Doc. 05-111 Filed 1-4-05; 8:45 am]
BILLING CODE 4160-01-S